Cayman Temozolomide-d3

Temozolomide-d₃ is intended for use as an internal standard for the quantification of temozolomide (Item No. 18863).¹ It is converted to MTIC in a non-enzymatic manner under physiological conditions. Temozolomide is selectively cytotoxic to U87 and D54 glioblastoma cells, which do not express O⁶-methylguanine-DNA methyltransferase (MGMT), over MGMT-expressing T98G and U3054MG glioblastoma cells (IC₅₀s = 51, 12, 660, and 370 µM, respectively).² It increases survival in a Br23c glioblastoma orthotopic mouse xenograft model when administered at a dose of 15 mg/kg. Temozolomide, in combination with antibodies targeting CD47, decreases tumor volume and increases the number of tumor-infiltrating CD4⁺ and CD8⁺ T cells in a GL261 murine glioma model.³ Formulations containing temozolomide have been used in the treatment of glioblastoma multiforme (GBM) and refractory anaplastic astrocytoma.

WARNING This product is not for human or veterinary use.